NasdaqCM:NAOV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. More Details


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has NanoVibronix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NAOV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

43.5%

NAOV

-3.8%

US Medical Equipment

-2.4%

US Market


1 Year Return

-65.0%

NAOV

14.0%

US Medical Equipment

12.0%

US Market

Return vs Industry: NAOV underperformed the US Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: NAOV underperformed the US Market which returned 10.9% over the past year.


Shareholder returns

NAOVIndustryMarket
7 Day43.5%-3.8%-2.4%
30 Day17.3%-3.7%-6.5%
90 Day-62.9%11.0%8.4%
1 Year-65.0%-65.0%15.0%14.0%14.5%12.0%
3 Year-87.2%-87.2%66.4%62.1%34.8%25.8%
5 Year-79.5%-79.5%134.4%116.6%82.1%61.6%

Price Volatility Vs. Market

How volatile is NanoVibronix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NanoVibronix undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether NanoVibronix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NanoVibronix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is NanoVibronix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoVibronix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NanoVibronix performed over the past 5 years?

-14.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NAOV is currently unprofitable.

Growing Profit Margin: NAOV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NAOV is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.

Accelerating Growth: Unable to compare NAOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NAOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: NAOV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is NanoVibronix's financial position?


Financial Position Analysis

Short Term Liabilities: NAOV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NAOV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NAOV has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NAOV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NAOV has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NAOV is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is NanoVibronix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NAOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NAOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NAOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NAOV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NAOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Brian Murphy (63 yo)

3.92yrs

Tenure

US$511,692

Compensation

Mr. Brian M. Murphy has been the Chief Executive Officer of NanoVibronix Inc. since October 13, 2016. Mr. Murphy has sales, operations and general management experience in medical devices and medical techn ...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD511.69K) is about average for companies of similar size in the US market ($USD606.89K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Brian Murphy
CEO & Director3.92yrsUS$511.69kno data
Stephen Brown
Consultant1.33yrsUS$200.53k0%
$ 0
James Cardwell
Chief Financial Officer1.33yrsno datano data
Amir Rippel
Vice President of Marketingno datano datano data
Lindsey Harrison
Vice President of Salesno datano datano data
Harold Jacob
Chief Medical Officer & Director17yrsUS$10.59k0.20%
$ 22.1k

2.6yrs

Average Tenure

63.5yo

Average Age

Experienced Management: NAOV's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Brian Murphy
CEO & Director3.92yrsUS$511.69kno data
Harold Jacob
Chief Medical Officer & Director17yrsUS$10.59k0.20%
$ 22.1k
Shalom Hirschman
Member of Medical Advisory Boardno datano datano data
Thomas Mika
Independent Director5.42yrsno data0%
$ 0
Christopher Fashek
Independent Chairman of the Board3.83yrsUS$150.00k0.20%
$ 21.5k
Dennis Maki
Member of Medical Advisory Boardno datano datano data
Phillip Hanno
Member of Medical Advisory Boardno datano datano data
Samuel Pinchas
Member of Medical Advisory Boardno datano datano data
Yechezkiel Caine
Member of Medical Advisory Boardno datano datano data
Mitchell Schwaber
Member of Medical Advisory Boardno datano datano data
Nathan Keller
Member of Medical Advisory Boardno datano datano data
Michael Ferguson
Independent Director5.42yrsno data0%
$ 0

5.4yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NAOV's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 71.1%.


Top Shareholders

Company Information

NanoVibronix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoVibronix, Inc.
  • Ticker: NAOV
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$11.038m
  • Shares outstanding: 12.82m
  • Website: https://www.nanovibronix.com

Number of Employees


Location

  • NanoVibronix, Inc.
  • 525 Executive Boulevard
  • Elmsford
  • New York
  • 10523
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NAOVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015

Biography

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 06:25
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.